Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
AstraZeneca
Dow
Moodys

Last Updated: September 27, 2022

Details for Patent: 7,645,802


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,645,802
Title:Bupropion hydrobromide and therapeutic applications
Abstract:Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
Inventor(s): Oberegger; Werner (Burlington, CA), Maes; Paul (Chatillon, FR), Saleh; Mohammad Ashty (Oakville, CA), Jackson; Graham (Co. Kildare, IE)
Assignee: Biovail Laboratories International SRL. (St. Michael, BB)
Application Number:11/930,644
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,645,802
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 7,645,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,645,802

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006261788 See Plans and Pricing
Australia 2008285660 See Plans and Pricing
Australia 2008320915 See Plans and Pricing
Canada 2578626 See Plans and Pricing
Canada 2655596 See Plans and Pricing
Canada 2699588 See Plans and Pricing
Canada 2700733 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Baxter
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.